Veterans test daily cream to stop face skin cancers

NCT ID NCT05212246

Not yet recruiting Prevention Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a daily imiquimod cream applied to the face for 12 weeks can prevent new basal cell carcinomas (BCC) in 1,630 veterans at high risk. Participants apply either the active cream or a placebo and are followed for up to 3 years with skin exams. The goal is to see if the cream reduces new BCCs on the face compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imiquimod cream (5%)
What this could lead to: If it works, this could offer a way to prevent new basal cell skin cancers on the face in people at high risk.
What could go wrong: This is a large Phase 3 trial, but it only includes veterans and focuses on the face. Side effects like skin irritation may limit use, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

actinic keratosis Patient Compliance squamous cell carcinoma basal cell carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA

Contacts and locations

Locations

Providence VA Medical Center, Providence, RI

Providence, Rhode Island, 02908-4734, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.